Table 2.
Quantification of cytokines in ASAS+ patients and healthy control groups.
| ASAS+ (n = 443) | Controls (n = 79) | |||||
|---|---|---|---|---|---|---|
| Detectable samples (%) | Range (pg/ml) | Median detectable (pg/ml) | Detectable samples (%) | Range (pg/ml) | Median detectable (pg/ml) | |
| IL-31 | 270 (60.94%) | [0–122.88] | 7.67 | 14 (17.72%) | [0–16.85] | 0.00 |
| sCD40L | 419 (94.58%) | [0–1867.54] | 463.33 | 75 (94.94%) | [0–1337.77] | 318.70 |
| TNFα | 307 (69.30%) | [0–24.54] | 1.88 | 76 (96.20%) | [0–10.41] | 2.12 |
| IL-6 | 268 (60.50%) | [0–124.20] | 5.84 | 55 (69.62%) | [0–10.18] | 0.99 |
| IL-4 | 64 (14.44%) | [0–304.20] | 12.00 | 12 (15.19%) | [0–114.41] | 6.92 |
| IL-33 | 30 (6.77%) | [0–860.50] | 24.33 | 23 (29.11%) | [0–894.29] | 84.07 |
| DKK-1 | 434 (97.96%) | [0–134.48] | 27.57 | 79 (100.00%) | [2.46–21.52] | 11.27 |
| IL-1β | 112 (25.28%) | [0–30.62] | 0.82 | 29 (36.71%) | [0–2.42] | 0.16 |
| IL-10 | 8 (1.81%) | [0–40.36] | 16.49 | 7 (8.86%) | [0–37.64] | 13.76 |
| IL17-A | 3 (0.67%) | [0–4.20] | 2.73 | 4 (5.06%) | [0–2.34] | 1.78 |
| IL-17F | 26 (5.86%) | [0–126.60] | 34.16 | 5 (6.33%) | [0–119.75] | 42.79 |
| IL-21 | 7 (1.58%) | [0–184.80] | 89.30 | 1 (1.27%) | [0–70.05] | 70.05 |
| IL-22 | 2 (0.45%) | [0–87.39] | 46.70 | 2 (2.53%) | [0–9.37] | 7.23 |
| IL-23 | 5 (1.13%) | [0–267.3] | 61.37 | 0 (0.00%) | — | — |
| IL-25 | 10 (2.26%) | [0–6.46] | 1.71 | 3 (3.80) | [0–1.71] | 1.71 |
| IFNγ | 6 (1.35%) | [0–44.35] | 13.34 | 1 (1.27%) | [0–15.75] | 15.75 |
The median value among quantifiable samples is provided as is the percentage of detectable samples.